Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1982 Jun;13(6):835–840. doi: 10.1111/j.1365-2125.1982.tb01875.x

Nadolol in thyrotoxicosis.

N R Peden, T E Isles, I H Stevenson, J Crooks
PMCID: PMC1402037  PMID: 6124267

Abstract

1 Twenty outpatients with thyrotoxicosis received the non-selective beta-adrenoceptor antagonist nadolol as sole treatment for 3 weeks. 2 Clinical improvement as measured by reduction in thyrotoxicosis therapeutic index occurred during the first week of treatment and was continued thereafter, and was accompanied by a significant reduction in serum T3 and elevation of serum reverse T3. 3 As measured by reduction in exercise heart rate, during chronic dosing nadolol 160 mg once daily produced blockade of beta-adrenoceptors for 12 h in all patients and 24 h in all but 2. 4 Wide interindividual variability was noted in steady state plasma nadolol concentrations, in part related to age and renal function. 5 Steady state plasma nadolol concentrations were related to reduction in heart rate.

Full text

PDF
835

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. CROOKS J., WAYNE E. J., ROBB R. A. A clinical method of assessing the results of therapy in thyrotoxicosis. Lancet. 1960 Feb 20;1(7121):397–401. doi: 10.1016/s0140-6736(60)90334-2. [DOI] [PubMed] [Google Scholar]
  2. Dreyfuss J., Griffith D. L., Singhvi S. M., Shaw J. M., Ross J. J., Jr, Vukovich R. A., Willard D. A. Pharmacokinetics of nadolol, a beta-receptor antagonist: administration of therapeutic single- and multiple-dosage regimens to hypertensive patients. J Clin Pharmacol. 1979 Nov-Dec;19(11-12):712–720. doi: 10.1002/j.1552-4604.1979.tb01641.x. [DOI] [PubMed] [Google Scholar]
  3. Duchin K. L., Vukovich R. A., Dennick L. G., Groel J. T., Willard D. A. Effects of nadolol beta-blockade on blood pressure in hypertension. Clin Pharmacol Ther. 1980 Jan;27(1):57–63. doi: 10.1038/clpt.1980.9. [DOI] [PubMed] [Google Scholar]
  4. Feely J., Isles T. E., Ratcliffe W. A., Crooks J. Propranolol, triiodothyronine, reverse triiodothyronine and thyroid disease. Clin Endocrinol (Oxf) 1979 May;10(5):531–538. doi: 10.1111/j.1365-2265.1979.tb02111.x. [DOI] [PubMed] [Google Scholar]
  5. Feely J. Propranolol and the hypercalcaemia of thyrotoxicosis. Acta Endocrinol (Copenh) 1981 Dec;98(4):528–532. doi: 10.1530/acta.0.0980528. [DOI] [PubMed] [Google Scholar]
  6. Feely J., Stevenson I. H., Crooks J. Increased clearance of propranolol in thyrotoxicosis. Ann Intern Med. 1981 Apr;94(4 Pt 1):472–474. doi: 10.7326/0003-4819-94-4-472. [DOI] [PubMed] [Google Scholar]
  7. Feely J., Stevenson I. H., Crooks J. Propranolol dynamics in thyrotoxicosis. Clin Pharmacol Ther. 1980 Jul;28(1):40–44. doi: 10.1038/clpt.1980.128. [DOI] [PubMed] [Google Scholar]
  8. Frishman W. H. Nadolol: a new beta-adrenoceptor antagonist. N Engl J Med. 1981 Sep 17;305(12):678–682. doi: 10.1056/NEJM198109173051206. [DOI] [PubMed] [Google Scholar]
  9. Heyma P., Larkins R. G., Higginbotham L., Ng K. W. D-propranolol and DL-propranolol both decrease conversion of L-thyroxine to L-triiodothyronine. Br Med J. 1980 Jul 5;281(6232):24–25. doi: 10.1136/bmj.281.6232.24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. How J., Khir A. S., Bewsher P. D. The effect of atenolol on serum thyroid hormones in hyperthyroid patients. Clin Endocrinol (Oxf) 1980 Sep;13(3):299–302. doi: 10.1111/j.1365-2265.1980.tb01056.x. [DOI] [PubMed] [Google Scholar]
  11. Ivashkiv E. Fluorometric determination of nadolol in human serum and urine. J Pharm Sci. 1977 Aug;66(8):1168–1172. doi: 10.1002/jps.2600660831. [DOI] [PubMed] [Google Scholar]
  12. Jones G. R., Lazarus J. H., Wynford-Thomas D. A study of long acting propranolol in the early management of hyperthyroidism. Br J Clin Pharmacol. 1981 Dec;12(6):825–828. doi: 10.1111/j.1365-2125.1981.tb01314.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Jones M. K., John R., Jones G. R. The effect of oxprenolol, acebutolol and propranolol on thyroid hormones in hyperthyroid subjects. Clin Endocrinol (Oxf) 1980 Oct;13(4):343–347. doi: 10.1111/j.1365-2265.1980.tb03394.x. [DOI] [PubMed] [Google Scholar]
  14. Lindsay R., Ramsay L. E., Hettiarrachchi J., Davies D. L., Beastall G. H. Serum and urine phosphate during short-term beta-adrenergic blockade in healthy men. Clin Pharmacol Ther. 1978 Dec;24(6):650–653. doi: 10.1002/cpt1978246650. [DOI] [PubMed] [Google Scholar]
  15. McDevitt D. G., Nelson J. K. Comparative trial of atenolol and propranolol in hyperthyroidism. Br J Clin Pharmacol. 1978 Sep;6(3):233–237. doi: 10.1111/j.1365-2125.1978.tb04590.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Murchison L. E., Bewsher P. D., Chesters M. I., Ferrier W. R. Comparison of propranolol and practolol in the management of hyperthyroidism. Br J Clin Pharmacol. 1976 Apr;3(2):273–277. doi: 10.1111/j.1365-2125.1976.tb00603.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Murchison L. E., How J., Bewsher P. D. Comparison of propranolol and metoprolol in the management of hyperthyroidism. Br J Clin Pharmacol. 1979 Dec;8(6):581–587. doi: 10.1111/j.1365-2125.1979.tb01048.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Nelson J. K., McDevitt D. G. Comparative trial of propranolol and practolol in hyperthyroidism. Br J Clin Pharmacol. 1975 Oct;2(5):411–416. doi: 10.1111/j.1365-2125.1975.tb00549.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Nilsson O. R., Karlberg B. E., Kågedal B., Tegler L., Almqvist S. Non-selective and selective beta-1-adrenoceptor blocking agents in the treatment of hyperthyroidism. Acta Med Scand. 1979;206(1-2):21–25. doi: 10.1111/j.0954-6820.1979.tb13463.x. [DOI] [PubMed] [Google Scholar]
  20. Nilsson O. R., Melander A., Tegler L. Effects and plasma levels of propranolol and metoprolol in hyperthyroid patients. Eur J Clin Pharmacol. 1980 Oct;18(4):315–320. doi: 10.1007/BF00561388. [DOI] [PubMed] [Google Scholar]
  21. Rubenfeld S., Silverman V. E., Welch K. M., Mallette L. E., Kohler P. O. Variable plasma propranolol levels in thyrotoxicosis. N Engl J Med. 1979 Feb 15;300(7):353–354. doi: 10.1056/NEJM197902153000707. [DOI] [PubMed] [Google Scholar]
  22. Saunders J., Hall S. E., Crowther A., Sönksen P. H. The effect of propranolol on thyroid hormones and oxygen consumption in thyrotoxicosis. Clin Endocrinol (Oxf) 1978 Jul;9(1):67–72. doi: 10.1111/j.1365-2265.1978.tb03573.x. [DOI] [PubMed] [Google Scholar]
  23. Seth J., Toft A. D., Irvine W. J. Simple solid-phase radioimmunoassays for total tri-iodothyronine and thyroxine in serum, and their clinical evaluation. Clin Chim Acta. 1976 May 3;68(3):291–301. doi: 10.1016/0009-8981(76)90394-6. [DOI] [PubMed] [Google Scholar]
  24. Shanks R. G., Hadden D. R., Lowe D. C., McDevitt D. G., Montgomery D. A. Controlled trial of propranolol in thyrotoxicosis. Lancet. 1969 May 17;1(7603):993–994. doi: 10.1016/s0140-6736(69)91797-8. [DOI] [PubMed] [Google Scholar]
  25. Siersbaek-Nielsen K., Hansen J. M., Kampmann J., Kristensen M. Rapid evaluation of creatinine clearance. Lancet. 1971 May 29;1(7709):1133–1134. doi: 10.1016/s0140-6736(71)91873-3. [DOI] [PubMed] [Google Scholar]
  26. Verhoeven R. P., Visser T. J., Doctor R., Hennemann G., Schalekamp M. A. Plasma thyroxine, 3,3',5-triiodothyronine and 3,3',5'-triiodothyronine during beta-adrenergic blockade in hyperthyroidism. J Clin Endocrinol Metab. 1977 May;44(5):1002–1005. doi: 10.1210/jcem-44-5-1002. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES